Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 2/3 1

Status

Recruiting 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 35INDUSTRY 6

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Neoplasms 2873Carcinoma, Non-Small-Cell Lung 2426Breast Neoplasms 2067Colorectal Neoplasms 1245Neoplasm Metastasis 1231Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 757Pancreatic Neoplasms 752Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 435Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 409Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 2Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Pancreatic Ductal Adenocarcinoma × Clear all
NCT07024615 2026-05-28

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Astellas Pharma Inc

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05257993 2026-04-13

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Onconic Therapeutics Inc.

Phase 1/2 Recruiting
71 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05846516 2026-04-01

A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

Boehringer Ingelheim

Phase 1 Active not recruiting
58 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT06528093 2026-02-03

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Boehringer Ingelheim

Phase 1 Terminated
8 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04827953 2024-12-30

NUMANTIA

Nelum Corp

Phase 1/2 Active not recruiting
28 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT06079346 2024-08-13

STOP-PC

Mateon Therapeutics

Phase 2/3 Recruiting
455 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡